Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-arm, Open-label, Dose-escalation Study of AFP Specific T Cell Receptor Transduced T Cells Injection（HRYZ-T102）in Patients With AFP Positive Advanced Hepatocellular Carcinoma and Other Solid Tumors

NCT06515314 is registered in ClinicalTrials.gov with Shanghai Ruiliyuan Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06515314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06515314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-arm, Open-label, Dose-escalation Study of AFP Specific T Cell Receptor Transduced T Cells Injection（HRYZ-T102）in Patients With AFP Positive Advanced Hepatocellular Carcinoma and Other Solid Tumors
Lead sponsor
Shanghai Ruiliyuan Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
October 17, 2024
Completion date
August 10, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic cell carcinoma